220 related articles for article (PubMed ID: 16157553)
1. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
[TBL] [Abstract][Full Text] [Related]
2. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.
Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
4. Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil.
de Carvalho LD; de Queiroz Mello FC; Redner P; Campos CED; de Souza Caldas PC; da Silva Lourenço MC; Ramos JP
J Glob Antimicrob Resist; 2019 Dec; 19():228-230. PubMed ID: 31100506
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China.
Guo Y; Cao Y; Liu H; Yang J; Wang W; Wang B; Li M; Yu F
Microbiol Spectr; 2022 Feb; 10(1):e0147521. PubMed ID: 35019778
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
8. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of Mycobacterium kansasii isolates in the State of São Paulo between 1995-1998.
Chimara E; Giampaglia CM; Martins MC; Telles MA; Ueki SY; Ferrazoli L
Mem Inst Oswaldo Cruz; 2004 Nov; 99(7):739-43. PubMed ID: 15654431
[TBL] [Abstract][Full Text] [Related]
10. Clofazimine for the Treatment of Mycobacterium kansasii.
Srivastava S; Gumbo T
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
[No Abstract] [Full Text] [Related]
11. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B
Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990
[TBL] [Abstract][Full Text] [Related]
13. [Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].
Ibarrola M; Baraia-Etxaburu J; Sánchez R; Teira R; Unzaga J; Miguel Santamaría J
Enferm Infecc Microbiol Clin; 2001 Feb; 19(2):80-2. PubMed ID: 11333577
[No Abstract] [Full Text] [Related]
14. [Distribution and drug resistance of nontuberculous
Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
[No Abstract] [Full Text] [Related]
15. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
16. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C
Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391
[TBL] [Abstract][Full Text] [Related]
17. In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.
Lin S; Hua W; Wang S; Zhang Y; Chen X; Liu H; Shao L; Chen J; Zhang W
BMC Microbiol; 2022 Jul; 22(1):175. PubMed ID: 35804298
[TBL] [Abstract][Full Text] [Related]
18. Whole genome sequence of Mycobacterium kansasii isolates of the genotype 1 from Brazilian patients with pulmonary disease demonstrates considerable heterogeneity.
Machado E; Vasconcellos SEG; Cerdeira C; Gomes LL; Junqueira R; Carvalho LD; Ramos JP; Redner P; Campos CED; Caldas PCS; Gomes APCS; Goldenberg T; Montes FF; Mello FCQ; Mussi VO; Lasunskaia E; Soolingen DV; Miranda AB; Rigouts L; Jong BC; Meehan CJ; Catanho M; Suffys PN
Mem Inst Oswaldo Cruz; 2018 Jun; 113(9):e180085. PubMed ID: 29947722
[TBL] [Abstract][Full Text] [Related]
19. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth.
Wallace RJ; Nash DR; Steele LC; Steingrube V
J Clin Microbiol; 1986 Dec; 24(6):976-81. PubMed ID: 3097069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
